"If I could predict what stocks will do, well then I would not be on this board."
I'll try to keep that in mind with any future predictions. Happy investing!
It all assumes that Regeneron executes their rollout effectively. Remember how Immunex botched their rollout of Enbrel? That's why they came to be acquired by Amgen. Also, it allowed Humira to be approved sooner and grow faster. Not saying that that's what will happen but if REGN is slow on the output and AMGN is a model of efficiency, the month may not make any difference.
R&D has an exemption from patent infringement. That includes clinical trials. A company is only infringing if they are selling another company's patent protected item while the patent is still in force. No money is made during development.
Go back to learning about stock splits. And, no, stock splits do not dilute a stock because the overall equity on the balance sheet doesn't change. LOL
You jinxed it by posting that you that you thought that the share price should be $160 soon. Karma pay back!